Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186
November 10, 2015 9:51 AM ESTPiper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More
Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
November 10, 2015 8:42 AM ESTLeerink Partners maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $187.00 (from $220.00), following the company's 3Q earnings report. JAZZs update included a modest topline miss driven by slower patient volume growth as the company experienced delays in Xyrem refills.
Analyst Jason... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
November 9, 2015 4:10 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More
